National Gaucher Foundation - Gaucher Disease
Slideshow Image 1
Slideshow Image 2
Slideshow Image 3

Shire - Human Genetic Therapies



  • Designed to replace glucocerebrosidase (the enzyme that is deficient or missing in people with Gaucher disease)
  • A prescription medicine for use in people with type 1 Gaucher disease
  • Derived from a human cell line
  • Designed to have an amino acid sequence identical to naturally occurring human protein

Your doctor can determine if VPRIV is right for you. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.

Find out more information about starting treatment with VPRIV.

For more information about Gaucher disease, including other types of the condition, go to